Tumor immune escape mechanisms that operate during metastasis

Current Pharmaceutical Biotechnology

Volumn 12, Issue 11, 2011, Pages 1923-1936

  Croci, D O ^a   Salatino, M ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Antitumor immunity; Cancer; Immune escape; Tumor microenvironment

Indexed keywords

GALECTIN 1;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER INVASION; CELL INTERACTION; CELL TRANSFORMATION; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; METASTASIS; NONHUMAN; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 82255165125     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798376987     Document Type: Review

References (156)

1. Swann, J. B.; Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest., 2007, 117(5), 1137-1146.
2. Lorusso, G.; Ruegg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol., 2008, 130(6), 1091-1103.
3. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol., 2004, 22, 329-360.
4. Koebel, C. M.; Vermi, W.; Swann, J. B.; Zerafa, N.; Rodig, S. J.; Old, L. J.; Smyth, M. J.; Schreiber, R. D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450(7171), 903-907.
5. Croci, D. O.; Zacarias Fluck, M. F.; Rico, M. J.; Matar, P.; Rabinovich, G. A.; Scharovsky, O. G. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother., 2007, 56(11), 1687-1700.
6. Joyce, J. A.; Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 2009, 9(4), 239-252.
7. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008, 27(45), 5904-5912.
8. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454(7203), 436-444.
9. Hicks, A. M.; Riedlinger, G.; Willingham, M. C.; Alexander-Miller, M. A.; Von Kap-Herr, C.; Pettenati, M. J.; Sanders, A. M.; Weir, H. M.; Du, W.; Kim, J.; Simpson, A. J.; Old, L. J.; Cui, Z. Transferable anticancer innate immunity in spontaneous regression/ complete resistance mice. Proc. Natl. Acad. Sci. USA, 2006, 103(20), 7753-7758.
10. Diefenbach, A.; Raulet, D.H. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev., 2002, 188, 9-21.
11. Ullrich, E.; Menard, C.; Flament, C.; Terme, M.; Mignot, G.; Bonmort, M.; Plumas, J.; Chaperot, L.; Chaput, N.; Zitvogel, L. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev., 2008, 19(1), 79-92.
12. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol., 2007, 81(1), 1-5.
13. Berzofsky, J. A.; Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med., 2009, 9(6), 667-672.
14. Terabe, M.; Berzofsky, J. A. The role of NKT cells in tumor immunity. Adv. Cancer Res., 2008, 101, 277-348.
15. Girardi, M. Immunosurveillance and immunoregulation by gammadelta T cells. J. Invest. Dermatol., 2006, 126(1), 25-31.
16. MacMicking, J.; Xie, Q.W.; Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol., 1997, 15, 323-350.
17. Takeda, K.; Hayakawa, Y.; Smyth, M.J.; Kayagaki, N.; Yamaguchi, N.; Kakuta, S.; Iwakura, Y.; Yagita, H.; Okumura, K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med., 2001, 7(1), 94-100.
18. Smyth, M.J.; Cretney, E.; Takeda, K.; Wiltrout, R.H.; Sedger, L.M.; Kayagaki, N.; Yagita, H.; Okumura, K. Tumor necrosis factor- related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med., 2001, 193(6), 661-670.
19. Hayakawa, Y.; Kelly, J.M.; Westwood, J.A.; Darcy, P.K.; Diefenbach, A.; Raulet, D.; Smyth, M.J. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol., 2002, 169(10), 5377-5381.
20. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol., 2002, 20, 395-425.
21. Schoenberger, S.P.; Toes, R.E.; van der Voort, E.I.; Offringa, R.; Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998, 393(6684), 480-483.
22. Albert, M.L.; Sauter, B.; Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 1998, 392(6671), 86-89.
23. Yu, P.; Spiotto, M.T.; Lee, Y.; Schreiber, H.; Fu, Y.X. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med., 2003, 197(8), 985-995.
24. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410(6832), 1107-1111.
25. Martini, M.; Testi, M.G.; Pasetto, M.; Picchio, M.C.; Innamorati, G.; Mazzocco, M.; Ugel, S.; Cingarlini, S.; Bronte, V.; Zanovello, P.; Krampera, M.; Mosna, F.; Cestari, T.; Riviera, A.P.; Brutti, N.; Barbieri, O.; Matera, L.; Tridente, G.; Colombatti, M.; Sartoris, S. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine, 2010, 28(20), 3548-3557.
26. Kaplan, D.H.; Shankaran, V.; Dighe, A.S.; Stockert, E.; Aguet, M.; Old, L.J.; Schreiber, R.D. Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7556-7561.
27. Teng, M.W.; Swann, J.B.; Koebel, C.M.; Schreiber, R.D.; Smyth, M.J. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol., 2008, 84(4), 988-993.
28. Smyth, M.J.; Crowe, N.Y.; Godfrey, D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International immunology, 2001, 13(4), 459-463.
29. Dighe, A.S.; Richards, E.; Old, L.J.; Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity, 1994, 1(6), 447-456.
30. Street, S.E.; Cretney, E.; Smyth, M.J. Perforin and interferongamma activities independently control tumor initiation, growth, and metastasis. Blood, 2001, 97(1), 192-197.
31. Shinkai, Y.; Rathbun, G.; Lam, K.P.; Oltz, E.M.; Stewart, V.; Mendelsohn, M.; Charron, J.; Datta, M.; Young, F.; Stall, A.M. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell, 1992, 68(5), 855-867.
32. Bolitho, P.; Street, S.E.; Westwood, J.A.; Edelmann, W.; Macgregor, D.; Waring, P.; Murray, W.K.; Godfrey, D.I.; Trapani, J.A.; Johnstone, R.W.; Smyth, M.J. Perforin-mediated suppression of Bcell lymphoma. Proc. Natl. Acad. Sci. USA, 2009, 106(8), 2723-2728.
33. Coates, P.J.; Lorimore, S.A.; Wright, E.G. Cell and tissue responses to genotoxic stress. J. Pathol., 2005, 205(2), 221-235.
34. Rabinovich, G.A.; Gabrilovich, D.; Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-296.
35. [Saraiva, M.; O'Garra, A. The regulation of IL-10 production by immune cells. Nature reviews, 10(3), 170-181.
36. Worschech, A.; Kmieciak, M.; Knutson, K.L.; Bear, H.D.; Szalay, A.A.; Wang, E.; Marincola, F.M.; Manjili, M.H. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res., 2008, 68(7), 2436-2446.
37. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol., 2006, 24, 99-146.
38. Gorsch, S.M.; Memoli, V.A.; Stukel, T.A.; Gold, L.I.; Arrick, B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res., 1992, 52(24), 6949-6952.
39. Thomas, D.A.; Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 2005, 8(5), 369-380.
40. Gorelik, L.; Flavell, R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med., 2001, 7(10), 1118-1122.
41. Blank, C.; Gajewski, T.F.; Mackensen, A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother., 2005, 54(4), 307-314.
42. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 2002, 8(8), 793-800.
43. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the in nate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 2004, 10(1), 48-54.
44. Germain, D.; Frank, D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res., 2007, 13(19), 5665-5669.
45. Dougan, M.; Dranoff, G. Immune therapy for cancer. Annu. Rev. Immunol., 2009, 27, 83-117.
46. Lowe, J.B. Glycosylation, immunity, and autoimmunity. Cell, 2001, 104(6), 809-812.
47. Demetriou, M.; Granovsky, M.; Quaggin, S.; Dennis, J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 Nglycosylation. Nature, 2001, 409(6821), 733-739.
48. Ley, K.; Kansas, G.S. Selectins in T-cell recruitment to nonlymphoid tissues and sites of inflammation. Nature reviews, 2004, 4(5), 325-335.
49. Priatel, J.J.; Chui, D.; Hiraoka, N.; Simmons, C.J.; Richardson, K.B.; Page, D.M.; Fukuda, M.; Varki, N.M.; Marth, J.D. The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity, 2000, 12(3), 273-283.
50. Toscano, M.A.; Bianco, G.A.; Ilarregui, J.M.; Croci, D.O.; Correale, J.; Hernandez, J.D.; Zwirner, N.W.; Poirier, F.; Riley, E.M.; Baum, L.G.; Rabinovich, G.A. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol., 2007, 8(8), 825-834.
51. Morgan, R.; Gao, G.; Pawling, J.; Dennis, J.W.; Demetriou, M.; Li, B. N-acetylglucosaminyltransferase V (Mgat5)-mediated Nglycosylation negatively regulates Th1 cytokine production by T cells. J. Immunol., 2004, 173(12), 7200-7208.
52. Dube, D.H.; Bertozzi, C.R. Glycans in cancer and inflammation- potential for therapeutics and diagnostics. Nature reviews, 2005, 4(6), 477-488.
53. Liu, F.T.; Rabinovich, G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer, 2005, 5(1), 29-41.
54. van Kooyk, Y.; Rabinovich, G.A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol., 2008, 9(6), 593-601.
55. Rabinovich, G.A.; Toscano, M.A. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nature reviews, 2009, 9(5), 338-352.
56. Salatino, M.; Croci, D.O.; Bianco, G.A.; Ilarregui, J.M.; Toscano, M.A.; Rabinovich, G.A. Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin. Biol. Ther., 2008, 8(1), 45-57.
57. He, J.; Baum, L.G. Presentation of galectin-1 by extracellular matrix triggers T cell death. J. Biol. Chem., 2004, 279(6), 4705-4712.
58. Matarrese, P.; Tinari, A.; Mormone, E.; Bianco, G.A.; Toscano, M.A.; Ascione, B.; Rabinovich, G.A.; Malorni, W. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem., 2005, 280(8), 6969-6985.
59. Stillman, B.N.; Hsu, D.K.; Pang, M.; Brewer, C.F.; Johnson, P.; Liu, F.T.; Baum, L.G. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol., 2006, 176(2), 778-789.
60. Rabinovich, G.A.; Ariel, A.; Hershkoviz, R.; Hirabayashi, J.; Kasai, K.I.; Lider, O. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology, 1999, 97(1), 100-106.
61. Ilarregui, J.M.; Croci, D.O.; Bianco, G.A.; Toscano, M.A.; Salatino, M.; Vermeulen, M.E.; Geffner, J.R.; Rabinovich, G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol., 2009, 10(9), 981-991.
62. Barrionuevo, P.; Beigier-Bompadre, M.; Ilarregui, J.M.; Toscano, M.A.; Bianco, G.A.; Isturiz, M.A.; Rabinovich, G.A. A Novel Function for Galectin-1 at the Crossroad of Innate and Adaptive Immunity: Galectin-1 Regulates Monocyte/Macrophage Physiology through a Nonapoptotic ERK-Dependent Pathway. J. Immunol., 2007, 178(1), 436-445.
63. Santucci, L.; Fiorucci, S.; Rubinstein, N.; Mencarelli, A.; Palazzetti, B.; Federici, B.; Rabinovich, G.A.; Morelli, A. Galectin- 1 suppresses experimental colitis in mice. Gastroenterology, 2003, 124(5), 1381-1394.
64. Garin, M.I.; Chu, C.C.; Golshayan, D.; Cernuda-Morollon, E.; Wait, R.; Lechler, R.I. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood, 2007, 109(5), 2058-2065.
65. Demydenko, D.; Berest, I. Expression of galectin-1 in malignant tumors. Exp. Oncol., 2009, 31(2), 74-79.
66. Camby, I.; Belot, N.; Lefranc, F.; Sadeghi, N.; de Launoit, Y.; Kaltner, H.; Musette, S.; Darro, F.; Danguy, A.; Salmon, I.; Gabius, H.J.; Kiss, R. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J. Neuropathol. Exp. Neurol., 2002, 61(7), 585-596.
67. Jung, E.J.; Moon, H.G.; Cho, B.I.; Jeong, C.Y.; Joo, Y.T.; Lee, Y.J.; Hong, S.C.; Choi, S.K.; Ha, W.S.; Kim, J.W.; Lee, C.W.; Lee, J.S.; Park, S.T. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int. J. Cancer, 2007, 120(11), 2331-2338.
68. van den Brule, F.A.; Waltregny, D.; Castronovo, V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J. Pathol., 2001, 193(1), 80-87.
69. Kreunin, P.; Yoo, C.; Urquidi, V.; Lubman, D.M.; Goodison, S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics, 2007, 7(2), 299-312.
70. Chen, Y.R.; Juan, H.F.; Huang, H.C.; Huang, H.H.; Lee, Y.J.; Liao, M.Y.; Tseng, C.W.; Lin, L.L.; Chen, J.Y.; Wang, M.J.; Chen, J.H.; Chen, Y.J. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J. Proteome Res., 2006, 5(10), 2727-2742.
71. Puchades, M.; Nilsson, C.L.; Emmett, M.R.; Aldape, K.D.; Ji, Y.; Lang, F.F.; Liu, T.J.; Conrad, C.A. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J. Proteome Res., 2007, 6(2), 869-875.
72. Perillo, N.L.; Pace, K.E.; Seilhamer, J.J.; Baum, L.G. Apoptosis of T cells mediated by galectin-1. Nature, 1995, 378(6558), 736-739.
73. Chung, C.D.; Patel, V.P.; Moran, M.; Lewis, L.A.; Miceli, M.C. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol., 2000, 165(7), 3722-3729.
74. Rabinovich, G.A.; Daly, G.; Dreja, H.; Tailor, H.; Riera, C.M.; Hirabayashi, J.; Chernajovsky, Y. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med., 1999, 190(3), 385-398.
75. Sotomayor, C.E.; Rabinovich, G.A. "Galectin-1 induces central and peripheral cell death: implications in T-cell physiopathology". Dev. Immunol., 2000, 7(2-4), 117-129.
76. Rubinstein, N.; Alvarez, M.; Zwirner, N.W.; Toscano, M.A.; Ilarregui, J.M.; Bravo, A.; Mordoh, J.; Fainboim, L.; Podhajcer, O.L.; Rabinovich, G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell, 2004, 5(3), 241-251.
77. Le, Q.T.; Shi, G.; Cao, H.; Nelson, D.W.; Wang, Y.; Chen, E.Y.; Zhao, S.; Kong, C.; Richardson, D.; O'Byrne, K.J.; Giaccia, A.J.; Koong, A.C. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol., 2005, 23(35), 8932-8941.
78. Daroqui, C.M.; Ilarregui, J.M.; Rubinstein, N.; Salatino, M.; Toscano, M.A.; Vazquez, P.; Bakin, A.; Puricelli, L.; Bal de Kier Joffe, E.; Rabinovich, G.A. Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol. Immunother., 2007, 56(4), 491-499.
79. Juszczynski, P.; Ouyang, J.; Monti, S.; Rodig, S.J.; Takeyama, K.; Abramson, J.; Chen, W.; Kutok, J.L.; Rabinovich, G.A.; Shipp, M.A. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA, 2007, 104(32), 13134-13139.
80. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 2004, 22, 531-562.
81. Fontenot, J.D.; Gavin, M.A.; Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol., 2003, 4(4), 330-336.
82. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M.L.; Knutson, K.L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 2004, 10(9), 942-949.
83. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature reviews, 2006, 6(4), 295-307.
84. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med., 2003, 198(12), 1875-1886.
85. Liu, V.C.; Wong, L.Y.; Jang, T.; Shah, A.H.; Park, I.; Yang, X.; Zhang, Q.; Lonning, S.; Teicher, B.A.; Lee, C. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol., 2007, 178(5), 2883-2892.
86. Fantini, M.C.; Becker, C.; Monteleone, G.; Pallone, F.; Galle, P.R.; Neurath, M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J. Immunol., 2004, 172(9), 5149-5153.
87. Peinado, H.; Quintanilla, M.; Cano, A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem., 2003, 278(23), 21113-21123.
88. Kudo-Saito, C.; Shirako, H.; Takeuchi, T.; Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snailinduced EMT of cancer cells. Cancer Cell, 2009, 15(3), 195-206.
89. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med., 2003, 9(10), 1269-1274.
90. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3- dioxygenase. J. Clin. Invest., 2007, 117(9), 2570-2582.
91. Nakamura, T.; Shima, T.; Saeki, A.; Hidaka, T.; Nakashima, A.; Takikawa, O.; Saito, S. Expression of indoleamine 2, 3- dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci., 2007, 98(6), 874-881.
92. Battaglia, A.; Buzzonetti, A.; Baranello, C.; Ferrandina, G.; Martinelli, E.; Fanfani, F.; Scambia, G.; Fattorossi, A. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother., 2009, 58(9), 1363-1373.
93. Matsuura, K.; Yamaguchi, Y.; Osaki, A.; Ohara, M.; Okita, R.; Emi, A.; Murakami, S.; Arihiro, K. FOXP3 expression of micrometastasis- positive sentinel nodes in breast cancer patients. Oncol. Rep., 2009, 22(5), 1181-1187.
94. Kawaida, H.; Kono, K.; Takahashi, A.; Sugai, H.; Mimura, K.; Miyagawa, N.; Omata, H.; Ooi, A.; Fujii, H. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res., 2005, 124(1), 151-157.
95. Viguier, M.; Lemaitre, F.; Verola, O.; Cho, M.S.; Gorochov, G.; Dubertret, L.; Bachelez, H.; Kourilsky, P.; Ferradini, L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol., 2004, 173(2), 1444-1453.
96. Guermonprez, P.; Valladeau, J.; Zitvogel, L.; Thery, C.;Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol., 2002, 20, 621-667.
97. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity., 1999, 10(3), 281-287.
98. Shigematsu, H.; Reizis, B.; Iwasaki, H.; Mizuno, S.; Hu, D.; Traver, D.; Leder, P.; Sakaguchi, N.; Akashi, K. Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin. Immunity., 2004, 21(1), 43-53.
99. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature, 1998, 392(6673), 245-252.
100. Steinman, R.M.; Pack, M.; Inaba, K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol. Rev., 1997, 156, 25-37.
101. Rieser, C.; Ramoner, R.; Holtl, L.; Rogatsch, H.; Papesh, C.; Stenzl, A.; Bartsch, G.; Thurnher, M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int., 1999, 63(3), 151-159.
102. Steinman, R.M.; Hawiger, D.; Nussenzweig, M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol., 2003, 21, 685-711.
103. Skoberne, M.; Somersan, S.; Almodovar, W.; Truong, T.; Petrova, K.; Henson, P.M.; Bhardwaj, N. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood, 2006, 108(3), 947-955.
104. Zhang, M.; Tang, H.; Guo, Z.; An, H.; Zhu, X.; Song, W.; Guo, J.; Huang, X.; Chen, T.; Wang, J.; Cao, X. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol., 2004, 5(11), 1124-1133.
105. Wakkach, A.; Fournier, N.; Brun, V.; Breittmayer, J.P.; Cottrez, F.; Groux, H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity, 2003, 18(5), 605-617.
106. Chorny, A.; Gonzalez-Rey, E.; Fernandez-Martin, A.; Pozo, D.; Ganea, D.; Delgado, M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl. Acad. Sci. USA, 2005, 102(38), 13562-13567.
107. Penna, G.; Amuchastegui, S.; Giarratana, N.; Daniel, K.C.; Vulcano, M.; Sozzani, S.; Adorini, L. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol., 2007, 178(1), 145-153.
108. Almand, B.; Resser, J.; Lindman, B.; Nadaf, S.; Clark, J.; Kwon, E.; Carbone, D.; Gabrilovich, D. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 2000, 6, 1755-1766.
109. Ishida, T.; Oyama, T.; Carbone, D.; Gabrilovich, D.I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J. Immunol., 1998, 161, 4842-4851.
110. Enk, A.H.; Jonuleit, H.; Saloga, J.; Knop, J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Intern. J. Cancer, 1997, 73, 309-316.
111. Nestle, F.O.; Burg, G.; Fah, J.; Wrone-Smith, T.; Nickoloff, B.J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 1997, 150, 641-651.
112. Chaux, P.; Favre, N.; Martin, M.; Martin, F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. International Journal of Cancer., 1997, 72, 619-624.
113. O'Donnell, R.K.; Mick, R.; Feldman, M.; Hino, S.; Wang, Y.; Brose, M.S.; Muschel, R.J. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett, 2007, 255(1), 145-152.
114. Matsuura, K.; Yamaguchi, Y.; Ueno, H.; Osaki, A.; Arihiro, K.; Toge, T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer, 2006, 106(6), 1227-1236.
115. Bembenek, A.; Li, J.; Loddenkemper, C.; Kemmner, W.; Stein, H.; Wernecke, K.D.; Schlag, P.M. Presence of mature DC-Lamp+ dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients. Eur. J. Surg. Oncol., 2008, 34(5), 514-518.
116. Movassagh, M.; Spatz, A.; Davoust, J.; Lebecque, S.; Romero, P.; Pittet, M.; Rimoldi, D.; Lienard, D.; Gugerli, O.; Ferradini, L.; Robert, C.; Avril, M.F.; Zitvogel, L.; Angevin, E. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res., 2004, 64(6), 2192-2198.
117. Laguens, G.; Coronato, S.; Laguens, R.; Portiansky, E.; Di Girolamo, V. Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. Immunol. Lett., 2002, 84(3), 159-162.
118. Treilleux, I.; Blay, J.Y.; Bendriss-Vermare, N.; Ray-Coquard, I.; Bachelot, T.; Guastalla, J.P.; Bremond, A.; Goddard, S.; Pin, J.J.; Barthelemy-Dubois, C.; Lebecque, S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res., 2004, 10(22), 7466-7474.
119. Kim, R.; Emi, M.; Tanabe, K.; Arihiro, K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. The Lancet Oncology, 2006, 7(12), 1006-1016.
120. Hartmann, E.; Wollenberg, B.; Rothenfusser, S.; Wagner, M.; Wellisch, D.; Mack, B.; Giese, T.; Gires, O.; Endres, S.; Hartmann, G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res., 2003, 63(19), 6478-6487.
121. Vermi, W.; Bonecchi, R.; Facchetti, F.; Bianchi, D.; Sozzani, S.; Festa, S.; Berenzi, A.; Cella, M.; Colonna, M. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol., 2003, 200(2), 255-268.
122. Wertel, I.; Polak, G.; Bednarek, W.; Barczynski, B.; Rolinski, J.; Kotarski, J. Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B. Clin. Cytom., 2008, 74(4), 251-258.
123. Gabrilovich, D.I.; Velders, M.; Sotomayor, E.; Kast, W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr- 1+ myeloid cells. J. Immunol., 2001, 166, 5398-5406.
124. Li, Q.; Pan, P.Y.; Gu, P.; Xu, D.; Chen, S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res., 2004, 64(3), 1130-1139.
125. Hayashi, T.; Hideshima, T.; Akiyama, M.; Raje, N.; Richardson, P.; Chauhan, D.; Anderson, K.C. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood, 2003, 102(4), 1435-1442.
126. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998, 92(11), 4150-4166.
127. Bronte, V.; Chappell, D.B.; Apolloni, E.; Cabrelle, A.; Wang, M.; Hwu, P.; Restifo, N.P. Unopposed production of granulocytemacrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol., 1999, 162(10), 5728-5737.
128. Terabe, M.; Matsui, S.; Park, J.M.; Mamura, M.; Noben-Trauth, N.; Donaldson, D.D.; Chen, W.; Wahl, S.M.; Ledbetter, S.; Pratt, B.; Letterio, J.J.; Paul, W.E.; Berzofsky, J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte- mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med., 2003, 198(11), 1741-1752.
129. Bunt, S.K.; Sinha, P.; Clements, V.K.; Leips, J.; Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol., 2006, 176(1), 284-290.
130. Bunt, S.K.; Yang, L.; Sinha, P.; Clements, V.K.; Leips, J.; Ostrand-Rosenberg, S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res., 2007, 67(20), 10019-10026.
131. Young, M.R.; Lozano, Y.; Ihm, J.; Wright, M.A.; Prechel, M.M. Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett, 1996, 104(2), 153-161.
132. Beck, C.; Schreiber, K.; Schreiber, H.; Rowley, D.A. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur. J. Immunol., 2003, 33(1), 19-28.
133. Bronte, V.; Wang, M.; Overwijk, W.; Surman, D.; Pericle, F.; Rosenberg, S.A.; Restifo, N.P. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol., 1998, 161, 5313-5320.
134. Kusmartsev, S.; Nefedova, Y.; Yoder, D.; Gabrilovich, D.I. Antigen- specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol., 2004, 172(2), 989-999.
135. Ghiringhelli, F.; Puig, P.E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGFbeta- secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med., 2005, 202(7), 919-929.
136. [Srivastava, M.K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res., 70(1), 68-77.
137. Hanson, E.M.; Clements, V.K.; Sinha, P.; Ilkovitch, D.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells down-regulate Lselectin expression on CD4+ and CD8+ T cells. J. Immunol., 2009, 183(2), 937-944.
138. Yang, L.; DeBusk, L.M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L.M.; Carbone, D.P.; Lin, P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 2004, 6(4), 409-421.
139. Shojaei, F.; Wu, X.; Malik, A.K.; Zhong, C.; Baldwin, M.E.; Schanz, S.; Fuh, G.; Gerber, H.P.; Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol., 2007, 25(8), 911-920.
140. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438(7069), 820-827.
141. Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Miyake, K.; Shibuya, M.; Akira, S.; Aburatani, H.; Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol., 2008, 10(11), 1349-1355.
142. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol., 2006, 8(12), 1369-1375.
143. Sinha, P.; Okoro, C.; Foell, D.; Freeze, H.H.; Ostrand-Rosenberg, S.; Srikrishna, G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol., 2008, 181(7), 4666-4675.
144. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 2004, 4(1), 71-78.
145. Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev., 2006, 25(3), 315-322.
146. Kusmartsev, S.; Gabrilovich, D.I. STAT1 signaling regulates tumor- associated macrophage-mediated T cell deletion. J. Immunol., 2005, 174(8), 4880-4891.
147. Saio, M.; Radoja, S.; Marino, M.; Frey, A.B. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cellassociated form of TNF and nitric oxide. J. Immunol., 2001, 167(10), 5583-5593.
148. Kusmartsev, S.; Gabrilovich, D.I. Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. J. Leukoc. Biol., 2003, 74(2), 186-196.
149. Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer, 2006, 42(6), 717-727.
150. Kusmartsev, S.; Gabrilovich, D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother., 2002, 51(6), 293-298.
151. Hagemann, T.; Robinson, S.C.; Schulz, M.; Trumper, L.; Balkwill, F.R.; Binder, C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis, 2004, 25(8), 1543-1549.
152. Lin, E.Y.; Pollard, J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res., 2007, 67(11), 5064-5066.
153. DeNardo, D.G.; Barreto, J.B.; Andreu, P.; Vasquez, L.; Tawfik, D.; Kolhatkar, N.; Coussens, L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 2009, 16(2), 91-102.
154. Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; Morton, K.E.; Mavroukakis, S.A.; Duray, P.H.; Steinberg, S.M.; Allison, J.P.; Davis, T.A.; Rosenberg, S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8372-8377.
155. Luo, Y.; Zhou, H.; Krueger, J.; Kaplan, C.; Lee, S.H.; Dolman, C.; Markowitz, D.; Wu, W.; Liu, C.; Reisfeld, R.A.; Xiang, R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest., 2006, 116(8), 2132-2141.
156. Suzuki, E.; Kapoor, V.; Jassar, A.S.; Kaiser, L.R.; Albelda, S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res., 2005, 11(18), 6713-6721.